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 Implication for health policy/practice/research/medical education:
It has been reported that GBV-C HIV coinfection can alter the course of HIV outcomes. This article focuses on impact of GBV-C on 
HIV viral load and also CD4 T cell counts in coinfected patients. The results can help the clinicians and researchers to evaluate the 
progress of HIV-positive-individuals to AIDS.
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Background: The picture that has emerged from studies investigating HIV infected peo-
ple with GBV-C viremia is that they have lower plasma HIV viral loads in comparison with 
HIV-positive people who did not have the GBV-C viremia.
Objectives: Since GBV-C HIV coinfection has not been studied in Iran, we have designed a 
survey to study the outcomes of GBV-C infection on HIV infected individuals.
Patients and Methods: We analyzed 78 serum samples from HIV-positive patients in Teh-
ran. The HIV positive statue was confirmed by Western blot in our laboratory. Next we 
detected GBV-C RNA by RT nested-PCR and divided our patient into GBV-C positive and 
GBV-C negative groups. The final step was measuring the CD4 count and HIV viral load 
and comparing the means of the CD4 count and HIV viral load in HIV-infected individu-
als in the GBV-C positive and GBV-C negative groups.
Results: We detected GBV-C RNA in 15 patients out of 78. The mean CD4 count was 607.13 
compared to 415.87 in the GBV-C negative group and the difference was significant (P = 
0.005). In contrast to the CD4 count there was no significant difference in HIV viral loads 
between HIV infected individuals in the GBV-C positive and GBV-C negative groups. 
Conclusion: Although there was no significant difference in the mean of the HIV viral 
load between the GBV-C positive and GBV-C negative groups, the significantly higher CD4 
mean in the GBV-C positive group compared with the GBV-C negative group suggests a 
beneficial effect of this coinfection.
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1. Background
GBV-C is a member of the Flaviviridae family and it is 
closely related to the hepatitis C virus (HCV) (1). A GBV-
C infection can persist for several years, but it usually 
causes no obvious clinical illness or death (2). In healthy 
blood donors, GBV-C infection persistence occurs at rates 
of 1.8 % (3). GBV-C infection clearance occurs in about 60% 
to 70% of immunocompetent GBV-C infected people with 39 GBV-C and HIV Co-infection Keyvani H et al.
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the appearance of anti-E2 viral glycoprotein antibodies 
(4, 5). Furthermore, GBV-C is a blood borne virus which 
can also be transmitted sexually, so a high prevalence of 
GBV-C infection is to be expected in human immunode-
ficiency virus (HIV) infected people (up to 35%) (3, 6). In 
1998, Heringlake et al. described an association between 
GBV-C viremia and prolonged survival in HIV-GBV-C coin-
fected patients compared with HIV-infected subjects (7). 
The results of some studies investigating the presence 
of GBV-C RNA in HIV-infected patients, showed that pa-
tients  with  GBV-C  viremia  had  lower  mortality  rates, 
higher baseline CD4 T cell counts and also a slower rate 
of decline in the number of CD4 T cells (7-12). In addition, 
the picture that has emerged from studies investigating 
HIV infected people with GBV-C viremia is that they have 
lower plasma HIV viral loads in comparison with HIV-
positive people who did not have the GBV-C viremia (7-
12). However, some studies did not find these potentially 
positive effects (13-15). To the best of our knowledge, in 
Iran the effects of HIV-GBV-C coinfection have not been 
widely evaluated and the prevalence of GBV-C in the HIV 
infected population has just been reported in our previ-
ous study (16). The coinfection of HIV-GBV-C can be con-
sidered variously depending on the population under 
study, HIV and GBV-C genotypes might be different in 
various geographical regions of the world. 
2. Objectives
The main aim of this study was to design a cross-sec-
tional  study  to  investigate  HIV-GBV-C coinfection  and 
its effects on HIV viral load and also CD4 T cell counts in 
coinfected patients in Tehran, the capital of Iran.
3. Patients and Methods
3.1. Study Population
The 78 patients involved in our cross-sectional study, 
were selected from the Imam Khomeini Hospital in Teh-
ran, they were classified as HIV positive by an ELISA, and 
we confirmed their HIV infection using the Western blot 
method. Data such as sex, age, transmission routes and 
finally HCV or HBV coinfection were collected from the 
patients’ files (Table 1). However, we were unable to follow 
up 7 patients out of the 78 for further information. The 
patients were between 5 and 54 years (mean 34.7 years) 
the group consisted of 87.5% males and 12.5% females. 
None of our patients were prescribed anti-HIV drugs. 
3.2. Detection of GBV-C Viremia
Viral RNA was extracted from 100µl of serum or plasma 
using the acid guanidinium isothiocyanate-phenol chlo-
roform  method.  For  C-DNA  synthesis,  RT-PCR  was  per-
formed at 42° C for 30 min. The C-DNA was stored at -20° 
C. Positive and negative controls were included in each 
run.  Positive  controls  were  provided  from  the  Keyvan 
laboratory and their GBV-C genome was sequenced at the 
Seqlab, Germany.
3.3. Nested-PCR
Two sets of primers were used in nested-PCR. 
External primers:
HG1: 5’GCCTATTGGTCAAGAGAGAC3’
HG2: 5’CACTATAGGTGGGTCTTAAG3’ 
Internal primers:
HG3: 5’GCGCACGGTCCACAGGTGTT3’
HG4: 5’GGGCGACGTGGACCGTACGT3’
The  first  PCR  round  was  run  for  30  cycles (94°C 
for 0.5 min, 55°C  for 1.5 min and 72°C for 1.5 min). 10µl of 
product from the first PCR round was used as a template 
in  the  second  PCR  round.  The  second  PCR  round  was 
for 35 cycles (94°C for 0.5 min, 55°C for 1.5 min and 72°C 
for 1.5 min). PCR products were separated by agarose gel 
electrophoresis and visualized by ethidium bromide 
staining.
3.4. HIV viral loads
Plasma HIV RNA load was quantified by a PCR (COBAS 
AMOLICOR HIV-1 Monitor kit, version 1.5; Roche Molecu-
lar Systems, Switzerland) 
3.5. CD4 Cell count
CD4 cells count was performed in the Imam Khomeini 
Hospital at the same time as viral loads were analyzed in 
our laboratory. 
3.6. Statistical analysis
Chi square and Man Whitney tests were used in com-
paring CD4 cells count and HIV viral loads between GBV-
C positive and negative groups in HIV-infected persons. 
A P value < 0.05 was considered significant All statistical 
analysis was done by SPSS software version 15. 
4. Results
Of the 78 patients investigated in our study the major-
ity of patients were in the 30-40 years age group, and the 
major transmission route was through intravenous drug 
usage (Table 1). In 15 out of 78 patients, GBV-C RNA was 
detectable. Therefore, we divided our patients into two 
groups; GBV-C positive and GBV-C negative patients. Hep-
atitis C virus (HCV) and hepatitis B virus (HBV) coinfec-
tion were also considerations in these patients. Among 
the  HIV-infected  individuals,  12  patients  were  infected 
with HCV and one was also infected with HBV (Table 2). 
Among the HIV-HCV infected patients, 3 patients also had 
GBV-C viremia. GBV-C viremia was not detected in the 
only patient coinfected with HCV/HBV/HIV (Table 2). The 
mean value of HIV viral loads and CD4 cell counts were 
evaluated in GBV-C positive and GBV-C negative groups 
(Table 3). Comparing the HIV viral load means between 
the GBV-C positive and GBV-C negative groups in HIV pos-
itive patients showed no significant difference (P = 0.43). 
In contrast, the mean of the CD4 cell counts among GBV–
C positive patients was significantly higher than in the 
GBV-C negative patients (P = 0.005).40 GBV-C and HIV Co-infection Keyvani H et al.
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5. Discussion
The effect of a GBV-C coinfection on the disease progress 
in HIV-infected individuals is incompletely understood. 
Our patients were mainly between 30-40 years old and 
their predominant transmission route was intravenous 
drug usage, which is in agreement with previous reports 
investigating the prevalence of HIV in Iran (17, 18). In our 
cross-sectional study, the CD4 count was higher in the 
GBV-C positive group compared with the GBV-C negative 
group in the HIV-positive individuals, and a significant 
difference (P = 0.005) was observed. However, there was 
no significant difference in the HIV viral loads between 
the GBV-C positive and negative groups (P = 0.43) (table 
3). Similar experiences have reported on the potential 
influence of GBV-C on CD4 counts (19-21) Taken together, 
Other researches demonstrate a significant association 
between the presence of GBV-C RNA in the serum of HIV-
infected individuals and higher CD4 counts (19-21). Hol-
lingsworth et al. found levels of CD4 counts below 200 
cell/µl in 25% of GBV-C positive patients compared with 
75% in the GBV-C negative patients (P = 0.0382) (19). In ad-
dition, the HIV-viral load tended to be lower, although it 
was not significant. Ibanez et al. and Bonacini et al. also 
reported a higher CD4 count in GBV-C positive patients, 
which was significant compared to CD4 counts in GBV-
C negative patients. However, in the latter two studies, 
HIV viral loads were not considered. In contrast, Lau et 
al. Wooly et al. and Goubau et al. failed to show any asso-
ciation between the presence of GBV-C RNA and a higher 
CD4 count in GBV-C positive patients among HIV-infect-
ed individuals (22-24).
Part of our results obtained in this current research is 
consistent  with  the  data  already  published.  However, 
there are explanations for the different results obtained 
in our study compared to the data collected from other 
studies, which found positive effects or no significant ef-
fects for GBV-C HIV co-infection. The main noticeable ex-
planation which needs to be considered is that, in most 
studies investigating GBV-C HIV coinfection, the inves-
tigators followed-up their patients for a period of time, 
in some cases over several years. Thus, they could mea-
sure CD4 counts and HIV viral loads at different periods 
through the years of follow-up. Also they could evaluate 
the progress of HIV-positive-individuals to AIDS, so they 
could compare the results they obtained during a period 
of time and also the mortality rate between GBV-C posi-
tive and GBV-C negative groups in HIV-positive individu-
als. 
Our study was a preliminary survey to assess the GBV-
C HIV coinfection statue in Iran. We did not have any 
information regarding GBV-C genotypes in Iran which 
With GBV-C RNA Without GBV-C RNA P value
Sex, No. (%)
Male
Female
13 (21)
1 (11.1)
49 (79)
8 (88.9)
0.67
0.67
Age, y, No. (%)
< 10
10 - 20
20 - 30
30 - 40
40 - 50
> 50
0 (0)
0 (0)
4 (26.7)
6 (18.2)
4 (22.2)
0 (0)
1 (100)
0 (0)
11 (73.3)
27 (81.8)
14 (77.8)
4 (100)
0.95
0.95
0.95
0.95
0.95
0.95
HIV transmission routes, %
Intravenous drug use
Heterosexual contact
Blood transmission
Mother to infant
Addict + Sexual
83.3
16.7
0
0
0
35.3
35.3
16.7
5.9
5.9
NE a
NE
NE
NE
NE
 Table 1. Patient Information
a Abbreviations: NE, not evaluated
GBV-C Positive, No. GBV-C Negative, No. Total, No.
HIV individuals with HCV coinfection 3 9 12
HIV individuals without HCV coinfection 12 53 65
HIV individuals with HCV/HBV coinfection 0 1 1
 Table 2. HCV/HBV Coinfection Statue in HIV-Infected Individuals
GBV-C Positive GBV-C Negative P value
CD4 count 607.13 415.87 0.005
HIV viral load 89480.73 92223.18 0.43
Table 3. CD4 Count and HIV Viral Load Means in GBV-C Positive and Nega-
tive Groups41 GBV-C and HIV Co-infection Keyvani H et al.
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might  have  a  different  effect  on  HIV  in  various  other 
geographical regions. In addition follow-up was not pos-
sible because the patients were out of reach. This was a 
limitation that we faced during this stage of the study. 
As noted above, although the CD4 count mean was sig-
nificantly higher in the GBV-C positive group, the HIV 
viral  load  mean  did  not  show  a  significant  difference 
between the GBV-C positive and negative groups. Other 
studies showed lower HIV viral loads in the plasma of 
HIV-positive people who had GBV-C viremia, so there is 
some discrepancy in the results from our research (7-
12). It is not unusual for different or even contradictory 
conclusions to be reported in the literature for similar 
subjects in the same field of research, as different results 
may be attributable to the experimental system used. In 
our study, although there was no significant difference 
between the mean of the HIV viral loads in the GBV-C 
positive and GBV-C negative groups, the mean of the CD4 
count was significantly higher in the GBV-C positive pa-
tients in comparison with the GBV-C negative patients. 
Our study’s results indicate a possible beneficial effect of 
a GBV-C coinfection with HIV. 
Ongoing attempts will be undertaken to design more 
studies of patients infected with GBV-C and the effects 
of GBV-C persistent infections. As well as the genotyping 
of GBV-C, surveying the possible effects of other kinds of 
coinfections such as HCV and HBV on HIV-infected indi-
viduals and ultimately following-up the patients enroll-
ing in such a project for a period of time, seem to be in-
teresting ideas warranting further research in Iran.
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